Kornimate/medical-research-clean huggingface dataset:
study of hallucinations in patients with borderline personality disorder

Conditions: Borderline Personality Disorder

Summary: hallucinations in borderline personality disorder are a frequent an serious trouble which have an important impact in patients lives. despite this, they are often ignored by nursing staff, and are not an important criteria in diagnostic and statistical manual (dsm) 5 and classification internationale des maladies (cim-10). the main objective of our study is to assess the prevalence of this trouble in borderline personality disorder (bpd) population, and to characterize the hallucinations in order to compare our results with those of international studies.

the borderline personality disorder (bpd) is a very common personality disorder which concerns about 1.35% of total population. it is characterized by an affective, emotional, social and professional instability and an important association with comorbidities like mood disorders, post-traumatic stress disorder, addictive problems and suicide mortality. hallucinations seem to be frequent in this personality disorder, but are not often taken in consideration by nursing staff because of massive need of attention of this kind of patient. at this moment there is no study of prevalence of this trouble in france in free environment. in the same way, there is no qualitative study about hallucinations. that is why we can do a lot of progress in this part of psychiatry. this research is an observational study of descriptive type. patients will be recruited in the different services. in this study, patients will have to pass different questionnaires (dib-r, des ii, thq, pcl-s, psas, qualitative questionnaire) in order to compare the characteristics between bdl patients with and without hallucinations. for that, the investigator will meet each patient twice, after information by the medical staff of the service and consent. during the first meeting, the investigator will get the socio-demographic characteristics, the verification of inclusion and non-inclusion criteria, and the dib-r questionnaire to know if the patient has really bpd and hallucinations or not. this is the same interview for all patients. during the second meeting, we will look for dissociative symptoms with des ii questionnaire, then traumatic symptoms and post-traumatic stress disorder with thq and pcl-s. the psas and qualitative questionnaire will be used for bpd patients with hallucinations.

Eligibility criteria:
inclusion criteria: * patient aged 18 and under 75 * patient with borderline personality disorder (formerly or newly diagnosed diagnosis) * patient having given his opposition to his participation in research exclusion criteria: * schizophrenia * major depressive episode characterized in progress * manic or hypomanic episode in progress * history of head trauma * stroke, parkinson's disease, dementia * autism * mental retardation * patient under the age of 75 * patient who does not read or speak french * patient unable to give consent (includes protected persons: guardianship, trusteeship) * incarcerated patient

Keywords: borderline hallucinations dissociation post-traumatic stress disorder
progesterone serum levels in subfertile female patients undergoing in vitro fertilisation (ivf)

Conditions: Infertility

Summary: this study is aimed to demonstrate that highly purified menotrophin produces significant lower progesterone serum levels during the follicular phase in comparison to follitropin alpha in the treatment of subfertile females undergoing an in vitro fertilisation (ivf) and to investigate if the progesterone serum levels might be a useful predictor for the success rate of the ongoing pregnancy rates


Eligibility criteria:
inclusion criteria: * signed informed consent * subfertile premenopausal female patients eligible for in vitro fertilisation (ivf) treatment * aged ≥34 and ≤42 years * body mass index of \>18 and \<28 kg/m\^2 * normal pelvic ultrasound at screening * no more than two previous gonadotrophin stimulated cycles of ivf or intracytoplasmic sperm injection (icsi) in the history of infertility treatment (gonadotrophin stimulated cycles not used for ivf or icsi do not count; clomifen cycles are no exclusion criterion) * at least 3 consecutive ovulatory menstrual cycles of 24-35 days * no fertility stimulating drugs at all * sperm of partner classified as normal according to world health organisation (who) 2010 criteria * clinically normal baseline haematology, clinical chemistry, and urinalysis values * negative serum hepatitis b surface antigen (hbsag), hepatitis c virus (hcv) and human immunodeficiency virus (hiv) antibody tests within the last 6 months prior to screening * endocrine test results within the clinically normal limits at screening exclusion criteria: * presence of any clinically relevant systemic disease (e.g., insulin-dependent diabetes mellitus) * a history of or current endocrine disease (excluding treated hypothyreosis), including polycystic ovary syndrome (pcos) and hyperprolactinaemia * a history of coagulation disorders * persistent ovarian cysts (\>3 months) * a history of hypersensitivity to any of the constituents of the study medication or related compounds * diagnosed poor (\<3 oocytes) responders to prior gonadotrophin stimulated art-cycle * history of severe ovarian hyperstimulation syndrome in former gonadotrophin stimulated assisted reproductive technology (art)-cycle
polypropylene mesh versus polytetrafluoroethylene (ptfe) mesh in inguinal hernia repair

Conditions: Physical Function; Pain; Hernia; Wound Infection; Postoperative Complication; Recurrence

Summary: to evaluate the safety and efficacy of the lichtenstein's hernioplasty using infinit® ptfe mesh, and to compare it with the traditional lichtenstein procedure performed with polypropylene mesh.


Eligibility criteria:
inclusion criteria: * \>18 \<65 years of age * diagnosis of unilateral inguinal hernia * able to provide written consent * bmi \< 35 * asa i-ii patients * non-complicated primary inguinal hernia performed in non-emergency setting and repaired with a lichtenstein's hernioplasty * informed consent exclusion criteria: * recurrent hernias * incarcerated hernia * bmi \> 35 * asa iii-iv patients * any condition preventing a correct evaluation of pain (non-cooperative patient, blind patient, drug addicted) * hypersensitivity to any drug in study * patients with an intra-operative findings of different pathology will be excluded from the study

Keywords: shrinkage postoperative pain and discomfort
galantamine to enhance cognitive behavioral therapy for cocaine abuse

Conditions: Cocaine Dependence

Summary: we are testing to see if galantamine, a learning enhancing medication, will help methadone maintained cocaine abusers with their learning and memory specific to cbt using an innovative cbt computer program.

we are proposing a randomized double blind clinical trial of galantamine and our innovative computer-assisted version of cbt, alone and in combination, to improve treatment outcome and cognitive functioning among cocaine users. the proposed study will be the first to evaluate a cognitive enhancing medication as a means of enhancing the effects of an extremely promising empirically validated behavioral therapy for addiction, and hence bridge cognitive neuroscience and behavioral therapies development. the aim is to conduct a 12 week randomized placebo controlled trial, using a 2x2 factorial model, that will evaluate the efficacy of adding computer assisted training in cbt ("cbt4cbt") and galantamine to standard treatment for 160 cocaine abusing or dependent methadone-maintained individuals. participants will be randomized to (1) standard treatment (tau) plus placebo, (2) tau plus galantamine, (3) tau plus cbt4cbt plus placebo, or (4) tau plus cbt4cbt plus galantamine.

Eligibility criteria:
inclusion criteria: * males and females between ages of 18 and 50 * enrolled in rnp methadone program and stable on methadone for at least 3 weeks * current cocaine abuse or dependence according to dsm-iv criteria * no current medical problems and normal ecg * if female, not currently pregnant or breast feeding and using reliable birth control * fluent in english and have at least a 6th grade reading level * can commit to 12 weeks of treatment and are willing to be randomized exclusion criteria: * current major psychiatric illness including mood, psychotic or anxiety disorder * history of major medical illnesses including asthma, chronic obstructive lung disease, gastrointestinal ulcer, hepatic or renal impairment, cardiac rhythm disturbances * use of medications including beta blockers and nasaids * known allergy to galantamine

Keywords: cocaine methadone cbt
vasopressor sat study

Conditions: Low Blood Pressure; Delirium; Critical Illness

Summary: to assess the impact of daily awakening from sedation on the amount of vasoactive medication required in the icu. the hypothesis of this proposal is that the amount of vasoactive drug required to maintain an adequate mean arterial blood pressure will be reduced during a daily awakening from sedation.

this observational study will compare mean arterial pressure and vasoactive drug dose recorded at two time points: 1. prior to awakening from sedation 2. during the awakening from sedation trial the vasoactive infusion will be titrated to a mean arterial pressure as determined by the medical team prior to study enrollment. each enrolled patient will have measurements taken only on the first day of enrollment. enrolled subjects will also have a delirium assessment using the cam-icu tool before the awakening from sedation trial and during the awakening from sedation trial.

Eligibility criteria:
inclusion criteria: * requiring mechanical ventilation through an endotracheal tube with infusion of sedative or analgesic agent for comfort * requiring vasoactive drug via central venous catheter for the treatment of shock exclusion criteria: * patients receiving dexmedetomidine as sedative
hemostasis in liver cirrhosis and hepatocellular cancer

Conditions: Hemostasis in Decompensated Liver Cirrhosis; Inflammation in Decompensated Liver Cirrhosis

Summary: evaluating hemostasis in decompensated liver cirrhosis with novel hemostatic assays.

the rebalanced hemostasis in liver cirrhosis is vulnerable and patients are prone to both bleeding and thrombosis. there are today no gold standard for evaluating the hemostasis and we will evaluate novel methods for this.

Eligibility criteria:
inclusion criteria: * patients with decompensated liver cirrhosis * 18 years or older. * healthy individuals 18 years or older will serve as controls. exclusion criteria: * • extrahepatic malignancy or recurrence of such within the last year. * diagnosis of non-cirrhotic coagulopathy, coagulation disorder or thrombophilia prior to inclusion. * diagnosis of hematological disease such as hematologic malignancies, non-cirrhotic thrombocytopenia or thrombocytosis, polycytemia vera, hemoglobinopathies * previous liver transplantation. * transfusions the last 7 days. * treatment with platelet inhibitors or anticoagulant except for prophylactic dosage of lmwh. if a prophylactic dose of lmwh has been used study sampling with addition of antifxa must be taken \>12 hours after the last injection.
virtual reality exposure therapy (vret) in psychomotor disadaptation syndrome

Conditions: Psychomotor Disadaptation Syndrome

Summary: according to demographic projections, by 2040, a quarter of the french population will be over 65. in this age group, the quality and quantity of visual, somaesthetic and vestibular information decline. this weakening of the balancing and the recurrence of falls lead to a restriction of activities of daily living and give rise to a fear of falling. psychomotor maladjustment syndrome (pmds) is a serious consequence of falls. a significant retropulsion when sitting or standing, as well as hypertonia characterize the posturobehavioral component of pmds. it coexists with a psychological component, marked by a fear of the anterior emptiness. a series of studies inducing fear and experimentally manipulating its intensity demonstrated a greater displacement of the center of pressure when subjects were exposed to elevated platforms. in addition to the subjective evaluation of fear, this emotion can be assessed by heart rate variability. despite the existence of standards and metrics adapted to the clinical setting, only one study investigated the association between the number of falls and heart rate variability in patients with neurodegenerative disorders. in recent years, cognitive and behavioral therapies using virtual reality (terv) have improved balance in patients with cardiovascular disease and parkinson's disease. virtual reality (vr) thus appears to be an interesting therapeutic approach to the treatment of psychological as well as postural-behavioral disorders of pdms. although the feasibility of a vr intervention has been tested in elderly people (aps) suffering from pmds, its effect has never been evaluated.


Eligibility criteria:
inclusion criteria: * patients diagnosed with pmds * ability to stand without human or technical assistance * falls efficacy scale international short (fes-i short) \> 13 * functional reach test (frt) score \< 26 cm * mini-mental state examination (mmse) score ≥ 20 exclusion criteria: * patients with disorders that may interfere with immersion in virtual reality (e.g. cerebellar syndromes, parkinsonian syndromes, hallucinations, sensory or neurocognitive disorders) * cybermalaise or cyberkinetosis

Keywords: virtual reality exposure therapy
the effect on decreasing chemotherapeutic toxicity and increasing anti-tumor effect of chinese herbs based on syndrome differentiation

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: to study the effect on decreasing chemotherapeutic toxicity and increasing anti-tumor treatment of chinese herbs based on syndrome differentiation


Eligibility criteria:
inclusion criteria: * histology and cytology diagnosed iiib or iv non-small-cell lung cancer (nsclc) and untreated; age \> 18 ages * sex unlimited; ecog (eastern cooperative oncology group) fitness score (performance status, ps)≤2. * white blood cell count ≥ 3 x 10e9 / l, neutrophils ≥1 x 109 p/l, hemoglobin≥80 g/l , platelet ≥100 x 10e9 / l * alt, ast, normal or less than 2 times, bilirubin is normal * serum level in the normal range;thr ecg is normal * expected survival time≥ 3 months or more; * agreed to the treatment combined traditional chinese medicine with western medicine exclusion criteria: * engaged in other clinical subjects * pregnant or lactating women, women in childbearing age refuse contraceptives during the trail * severe pneumonia, tuberculosis, lung abscess, myocarditis and other malignant tumor * severe damage of heart, liver and kidney (cardiac function grade 3 \~ 4, alt and/or ast 2 times more than normal , cr more the normal limit) * mental illness, refused to partner; cannot obtain informed consent
psychometric validation of the competitive attention test

Conditions: Attention Deficit Hyperactivity Disorder

Summary: this project aims at validating a new neuropsychological test to measure voluntary and involuntary attention for clinical use to diagnose attentional deficits. this project proposes: * a test-retest procedure in healthy subjects aged from 6 to 90 year-old; * testing in attention deficit hyperactivity disorder (adhd) patients before psychostimulant treatment; * testing in attention deficit hyperactivity disorder (adhd) patients before psychostimulant treatment.


Eligibility criteria:
inclusion criteria: healthy major participants: * age from 18 to 90 year-old * informed consent to participate in the study * no neurological or psychiatric disorder * no history of neuro-psychiatric disorder or neurodevelopmental type dysphasia, dyslexia, dyspraxia, attention deficit disorder healthy minor participants: * age from 6 to 17 year-old * informed consent of parents or guardians for the child's participation in the study * no neurological or psychiatric disorder * no history of neuro-psychiatric disorder or neurodevelopmental type dysphasia, dyslexia, dyspraxia, attention deficit disorder adhd minor patients: * age from 6 to 17 year-old * informed consent of parents or guardians for the child's participation in the study * adhd diagnosis with or without hyperactivity * no psychiatric history other than adhd. * for experience 3: treatment in progress. exclusion criteria: healthy major participants * age below 18 or above 90 year-old * unaffiliated or non-beneficiaries of the social security scheme healthy minor participants: * age below 6 or above 18 year-old * unaffiliated or non-beneficiaries of the social security scheme adhd minor patients: * age below 6 or above 18 year-old * unaffiliated or non-beneficiaries of the social security scheme

Keywords: attention deficit hyperactivity disorder attention distraction psychometric test neuropsychological test validating procedure psychostimulant
gaze contingent feedback in major depressive disorder (mdd)

Conditions: Depression, Unipolar; Depressive Disorder; Depressive Disorder, Major

Summary: the purpose of this study is to determine whether giving gaze-contingent feedback is an effective attention modification procedure, helping in the treatment of major depressive disorder (mdd)

the study examines giving depressive participants gaze-contingent feedback as a novel attention training procedure. half of the participants will receive contingent feedback while the other half would receive non-contingent "placebo" feedback.

Eligibility criteria:
inclusion criteria: * a signed consent form * men and women between the ages of 18 and 65. * meeting a current diagnosis of major depressive disorder (mdd) according to the dsm-iv * mdd as the primary diagnosis: in cases of co-morbidity, mdd will be deemed as the most distressing and clinically significant condition among the co-morbid disorders * stable pharmaco-therapy: participants receiving a pharmacological treatment who are taking a stable medication for at least 3 months before the beginning of the procedure. exclusion criteria: * psychotic episode in the past or the present time. * co-morbidity with any neurological disorder (i.e., epilepsy, brain injury). * another psychotherapeutic treatment during the study. * usage of neuroleptic medication. * change in medication status during the study. * substantial usage of drugs or alcohol in the present time. * poor judgment capacity (i.e., children under 18 and special populations). * high risk of suicide.

Keywords: depression cognitive bias modification mdd major depressive disorder attention bias modification treatment
feasibility and safety of additional injection of autologous platelet-rich stroma to surgical treatment of rectovaginal fistulas

Conditions: Rectovaginal Fistula; Anovaginal Fistula

Summary: is the addition of platelet-rich stroma (prs) injection, a form of autologous call therapy, to surgical treatment for rectovaginal fistula feasible and safe? the primary endpoints of this study are feasibility and safety until 12 months after surgery. secondary endpoints include rates of clinical and radiological closure, recurrence rates after clinical or radiological closure and unplanned re-interventions within 12-month post-surgery.


Eligibility criteria:
inclusion criteria: * patients presenting with significant symptoms of a rectovaginal fistula (rvf) * rvf confirmed on imaging or with a high suspicion based on imaging findings (magnetic resonance imaging \[mri\] and/or endoanal ultrasound \[eus\]) exclusion criteria: * patients with active proctitis * patients with the presence of associated (not properly drained)) pelvic abscess * patients with immune suppressed status * patients with hematological disorders * patients with any oncological event in the five years prior to study

Keywords: rectovaginal fistula anovaginal fistula platelet-rich stroma stromal vascular fraction platelet-rich plasma autologous cell therapy
a study to evaluate the safety and efficacy of afamelanotide in patients with xeroderma pigmentosum c and v

Conditions: Xeroderma Pigmentosum

Summary: the cuv152 study will evaluate the safety of afamelanotide in xp-c and xp-v patients, as well as the drug's ability to assist reparative processes following ultraviolet (uv) provoked dna damage of the skin. it will assess whether scenesse® increases the amount of uv light needed to cause dna damage of skin cells, as well as the extent of skin repair before and after treatment.


Eligibility criteria:
inclusion criteria: * male or female patient with a molecular-genetically confirmed diagnosis of xp-c or xp-v; * aged 18-75 years. exclusion criteria: * known allergy to afamelanotide or the polymer contained in the implant; * presence of severe hepatic disease or hepatic impairment; * renal impairment; * any other medical condition which may interfere with the study protocol; * existing melanoma; * female who is pregnant or lactating; * females of child-bearing potential (pre-menopausal, not surgically sterile) not using adequate contraceptive measures; * sexually active man with a partner of child-bearing potential who is not using adequate contraceptive measures; * use of any other prior and concomitant therapy which may interfere with the objective of the study; * participation in a clinical trial for an investigational agent.
efficacy and safety in patients with chronic lymphocytic leukemia (cll) treated with idelalisib and rituximab in the clinical practice: a gimema-eric study

Conditions: Chronic Lymphocytic Leukemia

Summary: the present study aims at obtaining more in-depth information on how patients with chronic lymphocytic leukemia treated with idelalisib and rituximab react to treatment.

this cohort study will recruit patients with treatment-naïve chronic lymphocytic leukemia (cll) with tp53 disruption (i.e. 17p- or tp53 mutations) or relapsed/refractory cll who were treated with idelalisib and rituximab between 01/07/2014 and 31/05/2017 at european centres adhering to the gimema group and the eric group.

Eligibility criteria:
inclusion criteria: * diagnosis of cll / small lymphocytic lymphoma (cll/sll) according to the world health organisation (who) classification 2008. * treatment with idelalisib and rituximab started between the date of country marketing authorization approval of idelalisib (ema approval 18/09/2014) and 31/05/2017 given at european centres adhering to the gimema group and the eric group. * one of the two following conditions must be satisfied: * previously untreated cll requiring therapy according to the nci criteria (hallek m et al, blood 2008)\] with deletion 17p13 and/or tp53 mutation. * relapsed refractory cll., i.e. patients who received at least one previous line of treatment using alkylating agents and/or purine analogues with or without monoclonal antibodies, or high dose steroids requiring therapy according to the nci criteria (hallek m et al, blood 2008) * age ≥ 18 years. * signed written informed consent, if applicable, according to ich/eu/gcp and national local law. exclusion criteria: * patients with cll treated with idelalisib within interventional clinical trials or outside the approved indication. * patients with: * transformation of cll to aggressive lymphomas (richter's syndrome). * hiv infection. * active and uncontrolled hcv and/or hbv infections or liver cirrhosis.

Keywords: chronic lymphocytic leukemia idelalisib rituximab